Eye Health

In a previous study, results showed that patients taking semaglutide could be at a higher risk of nonarteritic anterior ischemic optic neuropathy (NAION), causing blindness.

The therapy is now the first and only FDA-approved treatment that maintains vision with fewer treatments compared to standard-of-care injections.

Findings could inform future clinical practices on the treatment of DED for the more than 400 million people worldwide with the condition.

Viridian Therapeutics also said it has completed enrollment for a second phase 3 trial of veligrotug, THRIVE-2, and expects topline data to be available by the end of this year.

Recent studies on dry eye disease examined the efficacy of Vitamin D, platelet-rich plasma as a treatment option, and associations with certain systemic medications.

Researchers addressed the association between semaglutide use and the risk of nonarteritic anterior ischemic optic neuropathy.

Results of a new survey show that individuals with dry eye believe the condition is something “people must learn to live with.”

These aflibercept biosimilars are used to treat wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy.

The current study highlights the potential benefit of incorporating continuous glucose monitor (CGM) data into eye care assessments for patients with type 1 diabetes (T1D).

Priovant Therapeutics said that it intends to initiate a phase 3 program of brepocitinib in the second half of this year.

Clobetasol propionate ophthalmic suspension 0.05% is the first ophthalmic clobetasol propionate product approved by the FDA and is the first new ophthalmic steroid on the market in over 15 years.

Maintaining the structure and function of antibody biologics like faricimab is critical for their administration via intravitreal injection (IVI), a common treatment approach for retinal diseases.

The company that developed the treatment said it will benefit "millions" of patients.

A recent study showed a link between menopause and increased glaucoma risk, with estrogen-based treatment being a possible solution.

The study could lead to early diagnosis and treatment of age-related macular degeneration.

The researchers reported that there was no significant difference in the age-related macular degeneration prevalence among the 3 study groups.

According to the company, clinical outcomes for 78 dry eye patients treated at a single center, the Cleveland Eye Clinic, showcased the duration of efficacy of a single, first-time treatment of MGD using the TearCare System.

Mount Sinai study is the first to identify that heart attack, stroke and heart failure are linked to a specific type of age-related macular degeneration.

According to a study, use is linked to a lower prevalence of age-related macular degeneration in European populations.

According to NEXGEL, the patch is expected be available for ophthalmologists to offer to their patients in the first half of 2023.

The authors noted that the proportion of patients losing fewer than 15 letters from the baseline BCVA score in the study eye was comparable between the two groups.

Using 7-methylxanthine may be key to slowing myopia in pediatric cases.